German generics firm Stada has sold two of its Russian production plants, Makiz Pharma in Moscow and Skopin Pharmaceutical Plant, Ryazan, in a partial management buy-out. The disposals have cut Stada's workforce by 386 employees, a fact that the company trumpeted as having enable it to meet ahead of schedule "a significant restructuring goal" of its 2010 "Build the Future" programme: it has now cut its personnel by 10%, or around 800 full-time positions, ahead of the target of the end of 2013.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?